Novel imaging biomarkers predict outcomes in stage III unresectable non-small cell lung cancer treated with chemoradiation and durvalumab

Background The landmark study of durvalumab as consolidation therapy in NSCLC patients (PACIFIC trial) demonstrated significantly longer progression-free survival (PFS) in patients with locally advanced, unresectable non-small cell lung cancer (NSCLC) treated with durvalumab (immunotherapy, IO) ther...

Cijeli opis

Bibliografski detalji

Glavni autori:	Amit Gupta, Pingfu Fu, Nathan A Pennell, Mohamed Gad, Mohammadhadi Khorrami, Anant Madabhushi, Anas Saad, Pradnya Patil, Khalid Jazieh, Vidya Sankar Viswanathan, Prabhakar Rajiah, Charles J Nock, Michael Gilkey
Format:	Artigo
Jezik:	Inglês
Izdano:	BMJ Publishing Group 2022-03-01
Serija:	Journal for ImmunoTherapy of Cancer
Online pristup:	https://jitc.bmj.com/content/10/3/e003778.full
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!